Selective Stimulation of VEGFR2 Accelerates Progressive Renal Disease

Kang, 2001, Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease, Am J Kidney Dis, 37, 601, 10.1053/ajkd.2001.22087 Kang, 2001, Impaired angiogenesis in the remnant kidney model: I, J Am Soc Nephrol, 12, 1434, 10.1681/ASN.V1271434 Suga, 2001, Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy, Kidney Int, 60, 1297, 10.1046/j.1523-1755.2001.00935.x Kang, 2001, Impaired angiogenesis in the remnant kidney model: II, J Am Soc Nephrol, 12, 1448, 10.1681/ASN.V1271448 Yuan, 2003, Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1 alpha, Am J Pathol, 163, 2289, 10.1016/S0002-9440(10)63586-9 Kim, 2000, Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy, Kidney Int, 58, 2390, 10.1046/j.1523-1755.2000.00422.x Shimizu, 2004, Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis, J Am Soc Nephrol, 15, 2655, 10.1097/01.ASN.0000141038.28733.F2 de Vriese, 2001, Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes, J Am Soc Nephrol, 12, 993, 10.1681/ASN.V125993 Flyvbjerg, 2002, Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody, Diabetes, 51, 3090, 10.2337/diabetes.51.10.3090 Nakagawa, 2006, Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy, J Am Soc Nephrol, 17, 736, 10.1681/ASN.2005070759 Sato, 2008, The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy, Lab Invest, 88, 949, 10.1038/labinvest.2008.60 Barleon, 1996, Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1, Blood, 87, 3336, 10.1182/blood.V87.8.3336.bloodjournal8783336 Shih, 2003, Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity, J Clin Invest, 112, 50, 10.1172/JCI17808 Fong, 1995, Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium, Nature, 376, 66, 10.1038/376066a0 Kiba, 2003, VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice, Biochem Biophys Res Commun, 301, 371, 10.1016/S0006-291X(02)03033-4 Li, 2002, KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF, Hypertension, 39, 1095, 10.1161/01.HYP.0000018588.56950.7A Cooper, 1999, Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes, Diabetes, 48, 2229, 10.2337/diabetes.48.11.2229 Nakagawa, 2007, Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease, Am J Physiol Renal Physiol, 292, F1665, 10.1152/ajprenal.00495.2006 Nakagawa, 2009, Abnormal angiogenesis in diabetic nephropathy, Diabetes, 58, 1471, 10.2337/db09-0119 Li, 2000, Receptor-selective variants of human vascular endothelial growth factor, J Biol Chem, 275, 29823, 10.1074/jbc.M002015200 Gerber, 1998, Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway, J Biol Chem, 273, 30336, 10.1074/jbc.273.46.30336 Gille, 2001, Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2), J Biol Chem, 276, 3222, 10.1074/jbc.M002016200 Mu, 2009, Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism, Am J Physiol Renal Physiol, 296, F145, 10.1152/ajprenal.90430.2008 Nakagawa, 2007, Diabetic eNOS knockout mice develop advanced diabetic nephropathy, J Am Soc Nephrol, 18, 539, 10.1681/ASN.2006050459 Masaki, 2003, Heterogeneity of antigen expression explains controversy over glomerular macrophage accumulation in mouse glomerulonephritis, Nephrol Dial Transplant, 18, 178, 10.1093/ndt/18.1.178 Yuzawa, 1993, Antibody-mediated redistribution and shedding of endothelial antigens in the rabbit, J Immunol, 150, 5633, 10.4049/jimmunol.150.12.5633 Roberts, 2009, The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility, Kidney Int, 76, 546, 10.1038/ki.2009.168 Nakayama, 2010, Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney, Am J Pathol, 176, 2198, 10.2353/ajpath.2010.090316 Wu, 2000, Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation, J Biol Chem, 275, 5096, 10.1074/jbc.275.7.5096 Flyvbjerg, 2002, Compensatory glomerular growth after unilateral nephrectomy is VEGF dependent, Am J Physiol Endocrinol Metab, 283, E362, 10.1152/ajpendo.00007.2002 Senthil, 2003, Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy, Kidney Int, 64, 468, 10.1046/j.1523-1755.2003.00135.x Facemire, 2009, Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression, Hypertension, 54, 652, 10.1161/HYPERTENSIONAHA.109.129973 Iatropoulos, 1996, Proliferation markers, Exp Toxicol Pathol, 48, 175, 10.1016/S0940-2993(96)80039-X Ohashi, 2002, Peritubular capillary regression during the progression of experimental obstructive nephropathy, J Am Soc Nephrol, 13, 1795, 10.1097/01.ASN.0000018408.51388.57 Floege, 2008, A new look at platelet-derived growth factor in renal disease, J Am Soc Nephrol, 19, 12, 10.1681/ASN.2007050532 Eremina, 2006, Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival, J Am Soc Nephrol, 17, 724, 10.1681/ASN.2005080810 Thomas, 2000, Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease, J Am Soc Nephrol, 11, 1236, 10.1681/ASN.V1171236 Pettersson, 2000, Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor, Lab Invest, 80, 99, 10.1038/labinvest.3780013 Kremer, 1997, Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system, Cancer Res, 57, 3852 Hudkins, 2004, Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy, J Am Soc Nephrol, 15, 286, 10.1097/01.ASN.0000108522.79652.63 Hakroush, 2009, Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease, Am J Pathol, 175, 1883, 10.2353/ajpath.2009.080792 Ball, 2007, Vascular endothelial growth factor can signal through platelet-derived growth factor receptors, J Cell Biol, 177, 489, 10.1083/jcb.200608093 Veron, 2010, Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease, Kidney Int, 77, 989, 10.1038/ki.2010.64 Sison, 2010, Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling, J Am Soc Nephrol, 21, 1691, 10.1681/ASN.2010030295 Vitalone, 2008, Epithelial-to-mesenchymal transition in early transplant tubulointerstitial damage, J Am Soc Nephrol, 19, 1571, 10.1681/ASN.2007050580 Mann, 2008, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial, Lancet, 372, 547, 10.1016/S0140-6736(08)61236-2 Brandes, 2000, An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice, Proc Natl Acad Sci USA, 97, 9747, 10.1073/pnas.97.17.9747 Iwakiri, 2002, Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension, Am J Physiol Gastrointest Liver Physiol, 283, G1074, 10.1152/ajpgi.00145.2002 Yang, 2009, The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis, Arch Biochem Biophys, 489, 82, 10.1016/j.abb.2009.05.006 Webler, 2008, Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis, Am J Physiol Cell Physiol, 295, C1292, 10.1152/ajpcell.00230.2008 Nishimura, 2007, Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels, Diabetes, 56, 1517, 10.2337/db06-1749 Tam, 2009, Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells, PLoS One, 4, e4974, 10.1371/journal.pone.0004974 Pruna, 1997, Thrombomodulin is synthesized by human mesangial cells, Kidney Int, 51, 687, 10.1038/ki.1997.99